OR WAIT null SECS
Pfizer is set to supply global fund up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID, for low-and-middle-income countries.
Pfizer announced on Sept. 22, 2022 an agreement with Global Fund to supply up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID as part of its COVID-19 Response Mechanism (C19RM). The C19RM has been the primary vessel for providing grant support to low-and-middle-income countries to purchase COVID-19 tests, treatments, and personal protective equipment.
PAXLOVID treatment courses will be available through C19RM, subject to local regulatory approval by the 132 grant-eligible countries determined by Global Fund based on income classification and disease burden. According to a company press release, Pfizer anticipates supply to be available beginning in 2022, pending regulatory authorization and based on country demand. All low and lower-middle-income countries will pay a not-for-profit price, while upper-middle-income countries will pay the price defined in Pfizer’s tiered pricing approach.
“After so much disruption and loss due to COVID-19, we must continue to accelerate access to PAXLOVID as a treatment option for high-risk patients in all regions of the world along with test and treat programs that help get treatment quickly to those in need”, said Albert Bourla, chairman and CEO, Pfizer, in the press release. “This agreement with Global Fund is a critical step that will boost equitable access for high-risk patients in low-and-middle-income countries.”